Prostaglandin E<inf>2</inf> induces expression of MAPK phosphatase 1 (MKP-1) in airway smooth muscle cells

Publication Type:
Journal Article
Citation:
European Journal of Pharmacology, 2016, 782 pp. 1 - 5
Issue Date:
2016-07-05
Metrics:
Full metadata record
Files in This Item:
Filename Description Size
MED 27108790 am.pdfAccepted Manuscript Version155.25 kB
Adobe PDF
©2016 Published by Elsevier B.V. Prostaglandin E2 (PGE2) is a prostanoid with diverse actions in health and disease. In chronic respiratory diseases driven by inflammation, PGE2 has both positive and negative effects. An enhanced understanding of the receptor-mediated cellular signalling pathways induced by PGE2 may help us separate the beneficial properties from unwanted actions of this important prostaglandin. PGE2 is known to exert anti-inflammatory and bronchoprotective actions in human airways. To date however, whether PGE2 increases production of the anti-inflammatory protein MAPK phosphatase 1 (MKP-1) was unknown. We address this herein and use primary cultures of human airway smooth muscle (ASM) cells to show that PGE2 increases MKP-1 mRNA and protein upregulation in a concentration-dependent manner. We explore the signalling pathways responsible and show that PGE2-induces CREB phosphorylation, not p38 MAPK activation, in ASM cells. Moreover, we utilize selective antagonists of EP2 (PF-04418948) and EP4 receptors (GW 627368X) to begin to identify EP-mediated functional outcomes in ASM cells in vitro. Taken together with earlier studies, our data suggest that PGE2 increases production of the anti-inflammatory protein MKP-1 via cAMP/CREB-mediated cellular signalling in ASM cells and demonstrates that EP2 may, in part, be involved.
Please use this identifier to cite or link to this item: